Biotechnology
Technology
Health

Applied Genetic Technologies

$3.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-1.57%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AGTC and other stocks, options, ETFs, and crypto commission-free!

About

Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. Read More The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Employees
78
Headquarters
Alachua, Florida
Founded
1999
Market Cap
69.40M
Price-Earnings Ratio
38.38
Dividend Yield
0.00
Average Volume
122.30K
High Today
$3.95
Low Today
$3.65
Open Price
$3.88
Volume
38.54K
52 Week High
$7.50
52 Week Low
$2.26

Collections

Biotechnology
Technology
Health
Therapy
Medical
2014 IPO
US
North America

News

NasdaqMay 7

Applied Genetic Technologies (AGTC) Q3 Earnings and Revenues Surpass Estimates

Applied Genetic Technologies (AGTC) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of a loss of $0.54 per share.

14
Yahoo FinanceMay 7

Applied Genetic Technologies: Fiscal 3Q Earnings Snapshot

ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Tuesday reported fiscal third-quarter net income of $11.5 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Alachua, Florida-based company said it had net income of 63 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 54 cents per share. The biotechnology company posted revenue of $21.3 million in the ...

12
NasdaqMay 7

AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended March 31, 2019. "Completing enrollment in the dose escalation portion of our Phase 1/2 trial in patients with achromatopsia due to mutations in the CNGB3 gene and the expansi...

10

Earnings

-$0.68
-$0.43
-$0.18
$0.07
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
-$0.58 per share
Actual
-$0.49 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.